State Bank of Bikaner and Jaipur (SBBJ) reported a 48% rise in its net profit at Rs127.5 crore in the second quarter of the 2010-11, driven by higher interest income.
The bank had net profit of Rs90.1 crore during the same period last fiscal, SBBJ said in a statement.
For the half-year ending 30 September 2010, SBBJ's net profit stood at Rs230.7 crore. During the half year, the bank's revenues increased by 37% to Rs800.6 crore from Rs583 crore in the same period last year.
The bank has declared an interim dividend at Rs7.2 per share for the financial year 2010-11.
On Tuesday, SBBJ shares shed 1.1% at Rs746 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.9% to 19,983 points.
Bajaj Auto Ltd (BAL) reported 69.3% jump in its net profit for the quarter ending 30 September to Rs682.1 crore from Rs402.8 crore on the back of its highest ever quarterly motorcycle sales.
The company's total revenues during the second quarter to end-September, rose 50% to Rs4341.8 crore from Rs2887.5 crore, same period last year, Bajaj Auto said in a release.
During the July-September period, Bajaj sold over 10 lakh units, up 45.7%, as against 6.9 lakh units in the corresponding period last fiscal. In the motorcycle segment, the company recorded its highest ever sales at 8.8 lakh units compared to 6 lakh units, a growth of 47.3%.
On Tuesday, BAL shares declined 0.6% to Rs1,512 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.9% to 19,983 points.
Bengaluru-based Biocon Ltd said it signed an agreement with Pfizer for global commercialisation of its biosimilar versions of insulin and insulin analog products, including recombinant human insulin, glargine, aspart and lispro. No financial details were provided.
According to the agreement, Pfizer will have exclusive rights to commercialise these products globally, with certain exceptions, including co-exclusive rights for all of the products with Biocon in Germany, India and Malaysia, Biocon said in a release.
Pfizer will also have co-exclusive rights with existing Biocon licensees with respect to some of the products. Biocon will remain responsible for the clinical development, manufacture and supply of these biosimilar insulin products, the release added.
On Tuesday, Biocon shares climbed 13% at Rs455 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.9% to 19,983 points.